Lixisenatide (LIXI), a short acting glucagon-like peptide-1 receptor agonist, was reported to reduce post-prandial glucose and provide a complementary effect when combined with basal insulin (BI). Analysis comparing the efficacy of LIXI combined with BI in Asians and Caucasians is lacking. A pooled analysis of 2 multi-national phase III studies, GetGoal-L and GetGoal-L-C, was performed to assess the efficacy of LIXI vs. placebo as add-on treatment to BI ± metformin in Asian and Caucasian patients with T2DM. After pooling the data, baseline characteristics were similar between Asians and Caucasians except body weight, BMI and BI dose which were higher in Caucasians. After 24 weeks, LIXI significantly reduced HbA1c in both ethnic groups compared to placebo, with no statistically significant difference between the 2 groups: Asian [LS mean (s.e.) (95%CI): -0.49 (-0.68 to -0.30)] and Caucasian [LS mean (s.e.) (95% CI): -0.45 (-0.63 to -0.26)]; P=0.24. There was also no significant interaction between ethnicity and treatment (P=0.63). ANCOVA analysis showed that treatment with LIXI contributed to an HbA1c reduction of -0.56% after adjustment of baseline HbA1c level in Asian patients and -0.41% in Caucasian patients. Addition of LIXI to BI ± metformin reduced HbA1c to a similar extent in both Caucasian and Asian T2DM patients.
R. Yuezhong: None. M. Liu: None. G. Wu: Employee; Self; Sanofi. X. Zhang: None. N. Cui: None.
Sanofi
